| Literature DB >> 31082473 |
Maura Faraci1, Tamara Diesch2, Myriam Labopin3, Arnaud Dalissier4, Arian Lankester5, Andrew Gennery6, Mikael Sundin7, Duygu Uckan-Cetinkaya8, Marc Bierings9, Anke M J Peters10, Martina Garwer11, Ansgar Schulz12, Gerard Michel13, Giovanna Giorgiani14, Bernd Gruhn15, Franco Locatelli16, Stefano Giardino17, Anne Uyttebroeck18, Fanny Rialland19, Maija Itäla-Remes20, Peter Dreger21, Peter J Shaw22, Victoria Bordon23, Paul G Schlegel24, Karin Mellgren25, Jose M Moraleda26, Katharine Patrick27, Pascale Schneider28, Charlotte Jubert29, Anita Lawitschka30, Nina Salooja31, Grzegorz W Basak32, Selim Corbacioglu33, Rafael Duarte34, Peter Bader35.
Abstract
Gonadal impairment is an important late effect with a significant impact on quality of life of transplanted patients. The aim of this study was to compare gonadal function after busulfan (Bu) or treosulfan (Treo) conditioning regimens in pre- and postpubertal children. This retrospective, multicenter study included children transplanted in pediatric European Society for Blood and Marrow Transplantation (EBMT) centers between 1992 and 2012 who did not receive gonadotoxic chemoradiotherapy before the transplant. We evaluated 137 patients transplanted in 25 pediatric EBMT centers. Median age at transplant was 11.04 years (range, 5 to 18); 89 patients were boys and 48 girls. Eighty-nine patients were prepubertal at transplant and 48 postpubertal. One hundred eighteen children received Bu and 19 Treo. A higher proportion of girls treated with Treo in the prepubertal stage reached spontaneous puberty compared with those treated with Bu (P = .02). Spontaneous menarche was more frequent after Treo than after Bu (P < .001). Postpubertal boys and girls treated with Treo had significantly lower luteinizing hormone levels (P = .03 and P = .04, respectively) compared with the Bu group. Frequency of gonadal damage associated with Treo was significantly lower than that observed after Bu. These results need to be confirmed in a larger population. Published by Elsevier Inc.Entities:
Keywords: Busulfan; Gonadal damage; Pubertal stage; Treosulfan
Year: 2019 PMID: 31082473 DOI: 10.1016/j.bbmt.2019.05.005
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742